indazoles has been researched along with Nausea in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.80) | 18.7374 |
| 1990's | 34 (66.67) | 18.2507 |
| 2000's | 1 (1.96) | 29.6817 |
| 2010's | 9 (17.65) | 24.3611 |
| 2020's | 2 (3.92) | 2.80 |
| Authors | Studies |
|---|---|
| Chin, S; Choi, JW; Kim, SG; Kim, YS; Yoo, JJ | 1 |
| Backes, F; Barretina-Ginesta, P; Baumann, K; Bradley, WH; Bruchim, I; DePont Christensen, R; Freyer, G; González-Martín, A; Graybill, W; Gupta, D; Haggerty, AF; Hoskins, P; Jardon, K; Li, Y; Lorusso, D; Lund, B; Malinowska, IA; Mangili, G; McCormick, C; Mirza, MR; Monk, BJ; Moore, RG; O'Cearbhaill, RE; Pothuri, B; Redondo, A; Rubio-Pérez, MJ; Shahin, MS; Sun, K; Vergote, I; Vulsteke, C | 1 |
| de Geeter, P; Goebell, PJ; Grünwald, V; Herrmann, E; Hogrefe, C; Marschner, N; Merling, M; Panic, A; Potthoff, K; Staehler, M; Vannier, C | 1 |
| Gunderson, CC; Matulonis, U; Moore, KN | 1 |
| Adjei, AA; Bishop, WR; Carr, D; Chun, P; Cooper, A; Dayananth, P; Deng, Y; Flaherty, KT; Fong, PC; Hwu, WJ; Kirschmeier, P; Long, BJ; Miselis, NR; Moreno, BH; Moschos, SJ; Ramanathan, RK; Ribas, A; Robert, L; Rubin, EH; Rubino, J; Rush, TS; Samatar, AA; Schiller, J; Shapira-Frommer, R; Shipps, GW; Sullivan, RJ; Tawbi, HA; Zhang, D | 1 |
| O'Cearbhaill, RE | 1 |
| Cresta, S; Damian, S; Gendreau, S; Mayer, IA; Morrissey, KM; Ng, VW; Rooney, I; Schöffski, P; Singel, SM; Spoerke, JM; Wildiers, H; Winer, E | 1 |
| Davis, ID; Deen, KC; Hawkins, RE; Sigal, E; Sternberg, CN | 1 |
| Arnold, JK; Edison, LA; Gerona, RR; Schwartz, MD; Steck, AR; Trecki, J | 1 |
| Dowlati, A; Gibson, DM; Hodge, JP; Hurwitz, HI; Merkle, EM; Pandite, L; Saini, S; Savage, S; Suttle, AB | 1 |
| Chen, Y; Garrett, M; Hee, B; Klamerus, KJ; LaBadie, RR; Mount, J; Ni, G; Pithavala, YK; Selaru, P; Toh, M; Tortorici, MA | 1 |
| Andrews, L; Fishman, M; Gorbunova, V; Jonasch, E; Larkin, J; Negrier, S; Olivier, K; Pyle, L; Staehler, M; Wood, L | 1 |
| Smith, IE | 2 |
| de Wet, M; Falkson, G; Rapoport, BL | 1 |
| Fukunaka, N; Ishioka, S; Itoh, E; Kitajima, Y; Kudo, R; Sagae, S; Sato, K | 1 |
| Chevallier, B | 1 |
| Furue, H; Niitani, H; Ogawa, N; Ohta, K; Suminaga, M; Taguchi, T | 2 |
| Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K | 1 |
| Aapro, MS | 1 |
| Mori, K; Suga, Y; Takahashi, T; Tominaga, K | 1 |
| Hiraoka, A; Kageyama, T; Kakishita, E; Masaoka, T; Matsuzawa, Y; Nagai, K; Okuda, K; Oshiba, S; Tatsumi, N; Uchino, H | 1 |
| Baù, MG; Berruti, A; Bottini, A; Buniva, T; Danese, S; Dogliotti, L; Farris, A; Moro, G; Porcile, G; Richiardi, G; Zola, P | 1 |
| Aguerri, MF; Alby, N; Giacchetti, S; Imbeaux, PH | 1 |
| Bremer, K | 1 |
| Marty, M | 1 |
| Blijham, GH | 1 |
| Diehl, V | 1 |
| Hacking, A | 1 |
| Dilly, S | 1 |
| Kamanabrou, D | 1 |
| Blijham, GH; Bots, MW; Dijkstra, HJ; Fehmers, MC; Keizer, HJ; Nortier, JW; Siegenbeek van Heukelom, L; Slee, PH; van der Wall, E; Veenhof, CH | 1 |
| Kaizer, L; Laberge, F; Latreille, J; O'Connell, G; Osoba, D; Pater, J; Stewart, D; Venner, P; Warr, D; Wilan, A | 1 |
| Bosanquet, N; Jones, AL; Lee, GJ | 1 |
| Aapro, M; Diehl, V; Kaye, SB; Khayat, D | 1 |
| Davis, A; Erlichman, C; Fine, S; Laberge, F; Lofters, W; Osoba, D; Rusthoven, J; Warr, D; Willan, A; Wilson, K | 1 |
| Amaral, D; Lemerle, J; Murdoch, RD; Southall, DP; Upward, J | 1 |
| Goa, KL; Plosker, GL | 1 |
| Falkson, CI; Falkson, G; Falkson, HC | 1 |
| Addelman, M; Erlichman, C; Fine, S; Murray, C; Warr, D | 1 |
| Nakao, I | 1 |
| Soukop, M | 1 |
| Caubel, M; Cupissol, DR; Serrou, B | 1 |
| Brown, GW; Butcher, ME; Kidgell, AE | 1 |
| Cantwell, BM; Carmichael, J; Edwards, CM; Harris, AL; Rapeport, WG; Thompson, S; Zussman, BD | 1 |
| Falkson, G; van Zyl, AJ | 1 |
| Cantwell, BM; Carmichael, J; Edwards, CM; Harris, AL; Rapeport, WG | 1 |
| Brunner, KW; Joss, RA; Pirovino, M; Richner, J; Rohrbach, D; Terrey, JP; Upward, J | 1 |
| Band, PR; Besner, JG; Coppin, CM; Eisenhauer, EA; Stewart, D; Weinerman, BH | 1 |
6 review(s) available for indazoles and Nausea
| Article | Year |
|---|---|
Management of the toxicities of common targeted therapeutics for gynecologic cancers.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Autoimmune Diseases; Bevacizumab; Diarrhea; Epistaxis; Fatigue; Female; Genital Neoplasms, Female; Headache; Hemorrhage; Humans; Hypertension; Indazoles; Intestinal Perforation; Molecular Targeted Therapy; Nausea; Neutropenia; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Proteinuria; Pyrimidines; Risk Assessment; Sulfonamides; Vomiting; Water-Electrolyte Imbalance | 2018 |
Review of experience with ondansetron and granisetron.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1993 |
Are granisetron and ondansetron equivalent in the clinic?
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Humans; Imidazoles; Indazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1992 |
Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
Topics: Animals; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Indazoles; Male; Nausea; Neoplasms; Serotonin Antagonists; Vomiting | 1991 |
[Gastrointestinal side effects of anticancer agents and their counter measures].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Granisetron; Humans; Indazoles; Nausea; Vomiting | 1990 |
Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Granisetron; Headache; Humans; Imidazoles; Indazoles; Indoles; Nausea; Ondansetron; Radiation Injuries; Radiotherapy; Serotonin Antagonists; Tropisetron; Vomiting | 1990 |
28 trial(s) available for indazoles and Nausea
| Article | Year |
|---|---|
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Double-Blind Method; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Nausea; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Quality of Life; Survival Analysis | 2019 |
First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Hypothyroidism; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Cell Line, Tumor; Diarrhea; Dogs; Dose-Response Relationship, Drug; Drug Eruptions; Drug Evaluation, Preclinical; Fatigue; Female; Humans; Indazoles; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nausea; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Rats; Triazoles; Xenograft Model Antitumor Assays; Young Adult | 2018 |
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Letrozole; Middle Aged; Nausea; Paclitaxel; Sulfonamides; Trastuzumab | 2018 |
An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anorexia; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hair Color; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Pyrimidines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides; Treatment Outcome | 2014 |
Phase I trial of pazopanib in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Anorexia; Cohort Studies; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrimidines; Sulfonamides; Vomiting | 2009 |
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
Topics: Adult; Aged; Axitinib; Cross-Over Studies; Diarrhea; Dietary Fats; Energy Intake; Fasting; Fatigue; Female; Food-Drug Interactions; Humans; Imidazoles; Indazoles; Male; Middle Aged; Nausea; Tablets; Young Adult | 2012 |
A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Infant, Newborn; Injections, Intravenous; Nausea; Vomiting | 1993 |
The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group.
Topics: Blood Pressure; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Indazoles; Male; Metoclopramide; Middle Aged; Nausea; Neoplasms; Pulse | 1993 |
[Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--optimal dose-finding study].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Vomiting | 1993 |
[Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--multi-centered placebo-controlled double-blind comparative study].
Topics: Administration, Oral; Antiemetics; Cisplatin; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Tablets; Vomiting | 1993 |
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granisetron; Humans; Indazoles; Lymphoma; Male; Middle Aged; Mitoxantrone; Nausea; Vomiting | 1993 |
[Granisetron oral phase III clinical trial--study on the inhibitory effect of granisetron for nausea/vomiting induced by chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Granisetron; Hodgkin Disease; Humans; Indazoles; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Vomiting | 1993 |
Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Nausea; Pilot Projects; Thrombocytopenia; Treatment Outcome; Vomiting | 1998 |
A single-blind study of the efficacy and safety of intravenous granisetron compared with alizapride plus dexamethasone in the prophylaxis and control of emesis in patients receiving 5-day cytostatic therapy. The Granisetron Study Group.
Topics: Adult; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Indazoles; Infusions, Intravenous; Male; Middle Aged; Nausea; Pyrrolidines; Single-Blind Method; Vomiting | 1992 |
A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Single-Blind Method; Vomiting | 1992 |
Fractionated chemotherapy--granisetron or conventional antiemetics? The Granisetron Study Group.
Topics: Adult; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Indazoles; Male; Metoclopramide; Middle Aged; Nausea; Pyrrolidines; Single-Blind Method; Vomiting | 1992 |
Oral granisetron--simple and effective: a preliminary report. The Granisetron Study Group.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Vomiting | 1992 |
Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Female; Granisetron; Humans; Indazoles; Infusions, Intravenous; Male; Middle Aged; Nausea; Vomiting | 1992 |
A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Netherlands; Serotonin Antagonists; Vomiting | 1992 |
A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
Topics: Antiemetics; Cisplatin; Dexamethasone; Diphenhydramine; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Indazoles; Male; Metoclopramide; Middle Aged; Nausea; Vomiting | 1992 |
Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Prochlorperazine; Serotonin Antagonists; Vomiting | 1991 |
Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
Topics: Animals; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Indazoles; Male; Nausea; Neoplasms; Serotonin Antagonists; Vomiting | 1991 |
High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Double-Blind Method; Drugs, Investigational; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Random Allocation; Serotonin Antagonists; Vomiting | 1990 |
A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
Topics: Cisplatin; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Serotonin Antagonists; Time Factors; Vomiting | 1990 |
A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
Topics: Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Headache; Humans; Indazoles; Male; Middle Aged; Nausea; Serotonin Antagonists; Time Factors; Vomiting | 1990 |
The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Serotonin Antagonists; Sex Factors; Time Factors; Vomiting | 1990 |
Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nausea; Pain; Pyrazoles; Testis; Testosterone | 1986 |
18 other study(ies) available for indazoles and Nausea
| Article | Year |
|---|---|
Pazopanib-induced severe acute liver injury: A case report.
Topics: Bilirubin; Biopsy; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Female; Hepatitis B; Humans; Indazoles; Jaundice; Kidney Neoplasms; Middle Aged; Nausea; Pyrimidines; Steroids; Sulfonamides; Tomography, X-Ray Computed; Ultrasonography; United States; Vomiting | 2021 |
Using PARP Inhibitors in Advanced Ovarian Cancer.
Topics: Anemia; Creatinine; Drug Administration Schedule; Drug Interactions; Exanthema; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Heart Rate; Humans; Hypertension; Indazoles; Leukopenia; Mutation; Myelodysplastic Syndromes; Nasopharyngitis; Nausea; Ovarian Neoplasms; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Thrombocytopenia; Transaminases; Vomiting | 2018 |
A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA.
Topics: Acidosis; Adolescent; Adult; Aggression; Anxiety; Cannabinoids; Delirium; Disease Outbreaks; Female; Georgia; Humans; Hyperglycemia; Hypokalemia; Indazoles; Male; Middle Aged; Nausea; Seizures; Tachycardia; Vomiting; Young Adult | 2015 |
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
Topics: Axitinib; Carcinoma, Renal Cell; Diarrhea; Dysphonia; Fatigue; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Nausea; Protein Kinase Inhibitors; Proteinuria; Vomiting | 2014 |
Repeated use of granisetron in patients receiving cytostatic agents.
Topics: Adult; Age Factors; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constipation; Female; Granisetron; Headache; Humans; Indazoles; Infusions, Intravenous; Male; Middle Aged; Nausea; Remission Induction; Serotonin Antagonists; Vomiting | 1993 |
[The prevention of CDDP-induced emesis with granisetron].
Topics: Antiemetics; Cisplatin; Female; Granisetron; Humans; Indazoles; Infusions, Intravenous; Nausea; Ovarian Neoplasms; Uterine Neoplasms; Vomiting | 1993 |
[Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin].
Topics: Adenocarcinoma; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granisetron; Humans; Indazoles; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Nausea; Vindesine; Vomiting | 1993 |
[Nausea and vomiting in chemotherapy].
Topics: Antineoplastic Agents; Clinical Protocols; Granisetron; Humans; Indazoles; Nausea; Vomiting | 1992 |
Dose granisetron remain effective over multiple cycles? The Granisetron Study Group.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Administration Schedule; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Serotonin Antagonists; Sex Factors; Vomiting | 1992 |
The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Drug Costs; Granisetron; Humans; Indazoles; Models, Theoretical; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1992 |
Caring for the cancer patient: managing emesis now. An interactive workshop. Proceedings of a satellite symposium to the 6th European Conference on Clinical Oncology. Florence, October 1991.
Topics: Antiemetics; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Vomiting | 1992 |
Who should receive a 5-HT3 antagonist?
Topics: Acute Disease; Antineoplastic Agents; Granisetron; Humans; Indazoles; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1992 |
Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Granisetron; Humans; Indazoles; Male; Nausea; Prognosis; Serotonin Antagonists; Time Factors; Vomiting | 1991 |
Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Aspartate Aminotransferases; Chromatography, High Pressure Liquid; Cisplatin; Doxorubicin; Drug Evaluation; Drug Tolerance; Granisetron; Humans; Indazoles; Nausea; Pyrazoles; Serotonin Antagonists; Vomiting | 1990 |
A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.
Topics: Adult; Aged; Antiemetics; Basal Metabolism; Chromatography, High Pressure Liquid; Cisplatin; Female; Granisetron; Half-Life; Humans; Indazoles; Male; Middle Aged; Nausea; Pyrazoles; Serotonin Antagonists | 1989 |
A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Tolerance; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Serotonin Antagonists; Vomiting | 1989 |
The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.
Topics: Cisplatin; Dose-Response Relationship, Drug; Female; Granisetron; Humans; Indazoles; Male; Nausea; Pyrazoles; Serotonin Antagonists | 1988 |
BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Pyrazoles; Vomiting | 1988 |